In colon cancer stages II and III, there were trends for better RFS (P=0.077) and CSS (P=0.085) with a high EZH2 index in patients receiving adjuvant chemotherapy (Figure 3, panel E), but not in patients with no adjuvant therapy (Figure 3, panel F). Here, EZH2 is linked to malignant colon neoplasm.